Emergent BioSolutions | EBS - Sales Revenues

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exact Sciences USD 878.38M 27.38M Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Ironwood Pharmaceuticals USD 122.06M 36.82M Sep/2025
Lexicon Pharmaceuticals USD 1.65M 520K Jun/2024
Lonza CHF 3.58B 63M Jun/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Myriad Genetics USD 205.7M 7.4M Sep/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pacira USD 179.52M 1.58M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma USD 25K 5M Sep/2024